Thrombolytic therapy administered longer after the onset of ischemic stroke than current recommendations did not demonstrate improved clinical outcomes as compared to placebo, according to a recent trial published in the New England Journal of Medicine.
Investigators have developed a new, first-of-its-kind sticker that enables clinicians to monitor the health of patients’ organs and deep tissues with a simple ultrasound device.
Recent work from the laboratory of Elena Martinelli, PhD, MPH, has discovered how inhibiting an immune cell singling pathway in a model of HIV-1 infection may promote immune responses and decrease viral persistence in conjunction with antiretroviral therapy.
Emergency departments that see fewer pediatric patients are more likely to give delayed diagnoses for serious medical conditions compared to those who see pediatric patients more often, according to a Northwestern Medicine study published in JAMA Pediatrics.
A type of white blood cell is responsible for growth and branching of blood vessels which supports tumor growth in colon cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.
An experimental drug may provide a new treatment option for some patients with rare incurable brain tumors, according to an analysis published in the Journal of Clinical Oncology.
Specific immunosuppressants and immunotherapy are not enough to prevent organ rejection in patients undergoing skin cancer treatment who have also received a kidney transplant, according to a clinical trial published in the Journal of Clinical Oncology.
Lisa Namatame, a first-year Physician Assistant (PA) student, was recently awarded a scholarship from the National Health Service Corps Scholarship Program supported by the U.S. Department of Health and Human Services’ Health Resources and Services Administration.
Brian Garibaldi, MD, MEHP, professor of Medicine and of Physiology at the Johns Hopkins University School of Medicine, has been named the Charles Horace Mayo Professor of Medicine and the inaugural director of the new Center for Bedside Medicine at Northwestern.
A two-year follow-up clinical trial found that a personalized cellular therapy treatment for relapsed or refractory B-cell lymphoma demonstrated high safety and improved overall survival in patients, according to findings published in Blood.